ClinConnect ClinConnect Logo
Search / Trial NCT06688539

E-cigarette Cessation in Adults Who Co-use Cannabis

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Nov 12, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

E Cigarettes Cannabis Treatment

ClinConnect Summary

This clinical trial is looking at ways to help adults who use both e-cigarettes and cannabis quit using e-cigarettes. The study will use a medication called varenicline, which is approved to help people stop smoking regular cigarettes, along with financial incentives to encourage participants. The researchers want to learn how tobacco and cannabis interact when someone tries to quit using e-cigarettes. If you are between 18 and 40 years old, use e-cigarettes regularly, and have used cannabis in the past month, you may qualify to participate.

Participants in the study will receive treatment for 12 weeks and will take varenicline to help with quitting e-cigarettes. It’s important to note that you don’t need to be looking to quit cannabis to take part in this trial. The study is taking place at three locations in South Carolina, and they are currently looking for people to join. If you have any serious health issues, currently smoke regular cigarettes, or are pregnant or breastfeeding, you may not be eligible. This trial seeks to provide valuable insights into helping individuals quit e-cigarettes while considering their cannabis use.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Between the ages of 18 and 40 years old
  • Use e-cigarettes daily or near daily in the past month
  • Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng/ml)
  • Be interested in quitting use of e-cigarettes
  • Must be willing to take varenicline for the standard 12-week course of treatment
  • Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\> 50 ng/ml)
  • Exclusion Criteria:
  • Any serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance
  • Use of cigarettes on 10+ days in the past 30
  • Currently pregnant or breastfeeding
  • Current use of medications with smoking cessation efficacy
  • Use of any medications that would interfere with varenicline

About Medical University Of South Carolina

The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.

Locations

Pickens, South Carolina, United States

Charleston, South Carolina, United States

Lancaster, South Carolina, United States

Patients applied

0 patients applied

Trial Officials

Erin A McClure, PhD

Principal Investigator

Medical University of South Carolina

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported